WO2024042040 - INJECTION ASSEMBLY
National phase entry:
Publication Number
WO/2024/042040
Publication Date
29.02.2024
International Application No.
PCT/EP2023/072949
International Filing Date
21.08.2023
Title **
[English]
INJECTION ASSEMBLY
[French]
ENSEMBLE D'INJECTION
Applicants **
SHL MEDICAL AG
Inventors
COYNE III, Martin Michael
LINARES MARTINEZ, Alejandra
FRANZESE, Christopher James
TURETSKY, Jacob Leon
NAOI, Yukiko
KAPEC, Jeffrey
HARTL, Joshua Thomas
LARROW, Chester Boyd
STEVENSON, Florence Olivia
JAMES, Thomas Daniel
FORD BRIGHAM, Katherine
ANDERSON, Madeleine Hayden
RINALDI, Amy Catherine
HAWTHORNE, James Thomas
BANNWART, Lukas
Priority Data
63/399,743
22.08.2022
US
22199270.4
30.09.2022
EP
63/451,699
13.03.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2530 | |
| EPO | Filing, Examination, Granting | 9717 | |
| Japan | Filing, Examination, Granting | 2172 | |
| South Korea | Filing, Examination, Granting | 2103 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,262
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
An injection assembly for medicament administration with a plurality of needles (3a, 3b, 3c, 3d), the injection assembly (1-2) comprising: a first needle (3a) for a first predefined medicament administration, a second needle (3b) for a second predefined medicament administration, and a needle spacer arrangement (5-2) configured to be removably attached to the skin of a user, the needle spacer arrangement (5-2) being configured to provide a spacing between the first needle (3a) and the second needle (3b), wherein the spacing is sized such that medicament administered by the first needle (3a) and the second needle (3b) are prevented from mixing subcutaneously and/or is larger than a diameter of an expected first skin wheal formed subcutaneously as a result of the first predefined medicament administration and a diameter of an expected second skin wheal formed subcutaneously as a result of the second predefined medicament administration.[French]
L’invention concerne un ensemble d'injection pour l'administration de médicament avec une pluralité d'aiguilles (3a, 3b, 3c, 3d), l'ensemble d'injection (1-2) comprenant : une première aiguille (3a) pour une première administration de médicament prédéfinie, une seconde aiguille (3b) pour une seconde administration de médicament prédéfinie, et un agencement d'espaceur d'aiguille (5-2) configuré pour être fixé de manière amovible à la peau d'un utilisateur, l'agencement d'espaceur d'aiguille (5-2) étant configuré pour fournir un espacement entre la première aiguille (3a) et la seconde aiguille (3b), l'espacement étant dimensionné de telle sorte que le médicament administré par la première aiguille (3a) et la seconde aiguille (3b) ne peut pas se mélanger par voie sous-cutanée et/ou est plus grand qu'un diamètre d'une première papule cutanée attendue formée par voie sous-cutanée suite à la première administration de médicament prédéfinie et un diamètre d'une seconde papule cutanée attendue formée par voie sous-cutanée suite à la seconde administration de médicament prédéfinie.